Targeting Cellular Senescence As A Therapeutic Strategy To Attenuate Pulmonary Fibrosis Associated With Metabolic Syndrome
Our bodies are amazing, but sometimes things go awry. For people with metabolic issues like obesity and type 2 diabetes, there’s an increased risk of developing a serious lung condition called pulmonary fibrosis, where lung tissue becomes scarred and stiff, making it hard to breathe. Scientists have been working to understand this connection better.
Recent findings point to a fascinating culprit: “senescent cells.” Imagine cells that have stopped dividing but are still active, like retired workers who keep sending out signals. These senescent cells accumulate in the body, especially with metabolic dysfunction, and release harmful substances that promote inflammation and scarring in the lungs. This process essentially drives the progression of lung damage.
But there’s good news! Researchers explored two promising strategies to tackle these problematic senescent cells. One approach involved a special type of drug called a “senolytic agent,” specifically MitoTam, which is designed to selectively eliminate senescent cells. In studies, this agent not only improved metabolic health, like blood sugar control and body fat reduction, but also significantly decreased the number of senescent cells in the lungs, reducing inflammation and scarring. The other strategy looked at the impact of weight loss through bariatric surgery in individuals with severe obesity. This also led to improved metabolic health and a reduction in senescent cells and their harmful signals in fat tissue.
These discoveries highlight that targeting senescent cells could be a powerful new way to treat pulmonary fibrosis linked to metabolic problems, offering hope for more effective therapies in the future.
Source: link to paper